Relevant bibliographies by topics / Soluble cytokeratin fragments

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Soluble cytokeratin fragments'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Soluble cytokeratin fragments.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Soluble cytokeratin fragments"

1

Marrakchi, R., S. Ouerhani, S. Benammar, K. Rouissi, R. Bouhaha, K. Bougatef, Y. Messai, I. Khadimallah, K. Rahal, and A. Ben Ammar-Elgaaied. "Detection of Cytokeratin 19 mRNA and CYFRA 21–1 (Cytokeratin 19 Fragments) in Blood of Tunisian Women with Breast Cancer." International Journal of Biological Markers 23, no. 4 (October 2008): 238–43. http://dx.doi.org/10.1177/172460080802300407.

Full text
Abstract:
Cytokeratin 19 (CK19) is an acidic protein of 40 kDa that is part of the cytoskeleton of epithelial cells. It is highly expressed by all epithelial cells and represents a useful indicator of epithelial differentiation. The soluble fragment of CK19 (CYFRA 21–1) can be a useful circulating tumor marker and can be detected in the serum of cancer patients. The development of metastasis in patients with cancer of epithelial origin is due to the migration of tumor cells from the original tumor to distant organs. In order to detect micrometastasis in patients with breast cancer, we evaluated and compared CK19 gene expression using RT-PCR in blood samples collected from 80 healthy women and 80 patients with localized or metastatic breast cancer. The concentration of the soluble CK19 fragment CYFRA 21–1 was measured in serum of all study subjects by radioimmunoassay employing specific monoclonal antibodies. The relationship between the expression of this molecular marker and clinical stage, tumor differentiation and CK19 mRNA transcripts was investigated. We found that CK19 mRNA expression in blood (as a direct index of the presence of circulating tumor cells) was not correlated with CYFRA 21–1.
APA, Harvard, Vancouver, ISO, and other styles
2

Sugama, Y., and S. Kitamura. "Clinical evaluation of soluble cytokeratin fragments in sera — a new marker for non small cell lung carcinoma." Lung Cancer 11 (June 1994): 43. http://dx.doi.org/10.1016/0169-5002(94)93936-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Barillo, Jorge Luiz, Cyro Teixeira da Silva Junior, Patricia Siqueira Silva, Joeber Bernardo Soares de Souza, Salim Kanaan, Analucia Rampazzo Xavier, and Elizabeth Giestal de Araujo. "Increased Cytokeratin 19 Fragment Levels Are Positively Correlated with Adenosine Deaminase Activity in Malignant Pleural Effusions from Adenocarcinomas." Disease Markers 2018 (2018): 1–6. http://dx.doi.org/10.1155/2018/2609767.

Full text
Abstract:
Adenosine deaminase (ADA) and cytokeratin 19 (CK19) are known pleural biomarkers. Although ADA in humans functions mainly in the immune system, it also appears to be associated with the differentiation of epithelial cells. Keratin filaments are important structural stabilizers of epithelial cells and potent biomarkers in epithelial differentiation. This study aimed to investigate the simultaneous presence of the ADA enzyme and CK19 fragments to assess epithelial differentiation in malignant and benign pleural fluids. Diagnosis of the cause of pleural effusion syndrome was confirmed by means of standard examinations and appropriate surgical procedures. An ADA assay, in which ADA irreversibly catalyzes the conversion of adenosine into inosine, was performed using a commercial kit. The CK19 assay was performed using a CYFRA 21-1 kit, developed to detect quantitative soluble fragments of CK19 using an electrochemiluminescence immunoassay. One hundred nineteen pleural fluid samples were collected from untreated individuals with pleural effusion syndrome due to several causes. ADA levels only correlated with CK19 fragments in adenocarcinomas, with high significance and good correlation (rho = 0.5145, P=0.0036). However, further studies are required to understand this strong association on epithelial differentiation in metastatic pleural fluids from adenocarcinomas.
APA, Harvard, Vancouver, ISO, and other styles
4

Giovanella, L., L. Ceriani, A. Ghelfo, and M. Maffioli. "Circulating Cytokeratin 19 Fragments in Patients with benign Nodules and Carcinomas of the Thyroid Gland." International Journal of Biological Markers 23, no. 1 (January 2008): 54–57. http://dx.doi.org/10.1177/172460080802300109.

Full text
Abstract:
Cytokeratin 19 (CK19) is an acidic protein of 40 kDa that is part of the cytoskeleton of epithelial cells and is highly expressed by differentiated thyroid carcinomas, mainly of the papillary subtype. The soluble fragments of CK19 (Cyfra 21.1) can be measured by immunometric assays employing specific monoclonal antibodies. The present study was planned to assess the serum expression of Cyfra 21.1 in patients with benign thyroid nodules and thyroid malignancies. We enrolled 135 patients with histologically proven benign thyroid nodules (n=79) and thyroid carcinomas (n=56). No differences were found in serum Cyfra 21.1 levels between patients with benign nodules and patients with carcinomas. When thyroid malignancies were subdivided according to tumor histology, serum Cyfra 21.1 increased significantly from classical differentiated thyroid carcinomas (papillary or follicular) to less differentiated or undifferentiated carcinomas (poorly differentiated or anaplastic). CK19 release into the bloodstream is strongly related to the apoptotic pathway, and particularly to hyperproliferation-related apoptosis. These pathways characterized anaplastic and poorly differentiated thyroid carcinoma but not classical forms of differentiated thyroid carcinoma. Consequently, Cyfra 21.1 may be regarded as a circulating marker of poorly differentiated and anaplastic thyroid carcinoma. Additionally, a role of Cyfra 21.1 as a dedifferentiation marker in patients with classical differentiated thyroid carcinomas may be postulated and should be explored by further focused studies.
APA, Harvard, Vancouver, ISO, and other styles
5

Senga, Yasuhiro, Go Kimura, Tomotaka Hattori, and Kazuhiro Yoshida. "Clinical evaluation of soluble cytokeratin 19 fragments (cyfra 21-1) in serum and urine of patients with bladder cancer." Urology 48, no. 5 (November 1996): 703–10. http://dx.doi.org/10.1016/s0090-4295(96)00253-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bombardieri, E., E. Seregni, A. Bogni, S. Ardit, S. Belloli, A. Busetto, B. Caniello, et al. "Evaluation of Cytokeratin 19 Serum Fragments (Cyfra 21–1) in Patients with Lung Cancer: Results of a Multicenter Trial." International Journal of Biological Markers 9, no. 2 (April 1994): 89–95. http://dx.doi.org/10.1177/172460089400900205.

Full text
Abstract:
Recently, a new immunometric assay (Cyfra 21–1) was developed to measure serum concentrations of a soluble fragment of cytokeratin subunit 19. With this method, supplied by Boehringer Mannheim (EIA Test Cyfra 21–1), an Italian multicenter trial was performed in patients with lung cancer. Cyfra 21–1 serum levels were determined in 568 normal subjects (blood donors), 607 patients with non-malignant diseases (491 respiratory diseases) and 730 patients with malignancies. In the latter group 584 had lung cancer. All these 584 patients had pathologically confirmed disease; 314 were epidermoid tumors, 166 adenocarcinomas, 88 small cell cancers and 16 large cell cancers. In the 568 healthy blood donors the mean Cyfra 21–1 value was 0.91 ng/ml (SD 0.47 ng/ml; range 0.05–2.90 ng/ml). A threshold of 1.9 ng/ml was chosen as the upper limit of normality. High levels of Cyfra21–1 were observed in patients with chronic hepatitis (positivity rate: 17/51–33.3%) and with pancreatitis (positivity rate 5/16 - 31.3%). In 114 out of 491 (23.2%) patients with respiratory diseases Cyfra 21–1 showed values greater than 1.9 ng/ml. The overall sensitivity (all stages) of Cyfra 21–1 in lung cancer was 65.6% (383/584). When the histology was considered the highest positivity rates were found in patients with squamous cell tumors (226/314; 72%) followed by adenocarcinomas (105/166; 63%). In patients with SCLC the global sensitivity was 52.3% (46/88). Higher sensitivity of Cyfra 21–1 was observed from stage I to stage IV (53.9% vs 85.7%; Chisquare: p < 0.01). When comparing patients in whom curative resections were possible (up to stage IIIa) with patients suffering from inoperable tumors, a significant difference in Cyfra 21–1 positivies was found (59% vs 81.5%; Chi square p < 0.01).
APA, Harvard, Vancouver, ISO, and other styles
7

Bodenmüller, H., B. Ofenloch-Hähnle, E. B. Lane, A. Dessauer, V. Böttger, and F. Donié. "Lung Cancer-Associated Keratin 19 Fragments: Development and Biochemical Characterisation of the New Serum Assay Enzymun-Test® Cyfra 21–1." International Journal of Biological Markers 9, no. 2 (April 1994): 75–81. http://dx.doi.org/10.1177/172460089400900203.

Full text
Abstract:
From a panel of 4 murine monoclonal antibodies directed against keratin 19 various antibody combinations were evaluated in solid-phase enzyme-linked sandwich immunoassays for detection of soluble keratin 19 fragments in patient sera. One of these antibody combinations, comprised of the monoclonal antibodies Ks 19.1 and BM 19.21, was selected for further development to a routine test (Enzymun-Test® CYFRA 21–1) because of its high diagnostic sensitivity and specificity for non-small cell lung carcinoma (NSCLC). Both antibodies are specific for keratin 19, no reactivity could be observed with cytokeratin 8 or 18. The epitopes of the two antibodies were determined to be within helix 2B of the rod romain. The epitope sequences lie within the sequence 311–335 for the catcher antibody Ks 19.1 and 346–367 for the detector antibody BM 19.21. These sequences are unique, as could be confirmed from sequence databases. The standard material for the assay was prepared from a cytoskeleton fraction of cultivated MCF-7 cells. Subsequent digestion of this fraction with chymotrypsin yielded a soluble and stable standard material. Both the standard material and the serum analyte appeared as oligomers when analysed on gel chromatography: the serum analyte appeared exclusively at a Mr of 100 ± 10 kD, whereas the standard material eluted in fractions corresponding to 100 ±10 kD and 450 kD. Due to the precise definition of the antigen and the localisation of the antibody binding sequences, Enzymun-Test® CYFRA 21–1 is one of the best characterised tumor markers so far.
APA, Harvard, Vancouver, ISO, and other styles
8

Gion, Massimo, Patrizia Boracchi, Ruggero Dittadi, Elia Biganzoli, Lucia Peloso, Carlo Gatti, Adriano Paccagnella, Alberto Rosabian, Orazio Vinante, and Sabrina Meo. "Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis." Breast Cancer Research and Treatment 59, no. 3 (February 2000): 211–21. http://dx.doi.org/10.1023/a:1006318112776.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Foa, P., E. Seregni, L. Santambrogio, M. Mezzetti, M. Sala, A. Iurlo, and E. Bombardieri. "1264 Cytokeratin 19 soluble fragments (CK19) determination in patients with non-small cell lung cancer (NSCLC): Comparison with TPA, CEA, SCC and NSE." European Journal of Cancer 31 (November 1995): S264. http://dx.doi.org/10.1016/0959-8049(95)96510-k.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kramer, G., S. Schwarz, L. Müller, J. Mauermann, M. Remzi, and M. Marberger. "574Quantity and mode of tumour cell death measured by soluble cytokeratin-18 fragments as clinical response parameter after chemotherapy of hormone-refractory prostate cancer (HRPC)." European Urology Supplements 4, no. 3 (March 2005): 146. http://dx.doi.org/10.1016/s1569-9056(05)80578-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Soluble cytokeratin fragments"

1

Šafanda, Martin. "Využití nových biomarkerů pro zefektivnění diagnostiky a optimalizace léčby nádorů trávicího traktu." Doctoral thesis, 2017. http://www.nusl.cz/ntk/nusl-366027.

Full text
Abstract:
Utilisation of New Biomarkers for the Optimalization of Diagnostics and Therapy of Tumors of the Gastrointestinal Tract Introduction: Tumor markers are standard diagnostic tools. They are mainly used to monitor the course of the disease and to check the efficacy of the treatment. It is important to observe dynamics. Changing the level of the biomarker can prevent clinical manifestation and lead to early diagnosis of relapse, which in turn means improving the quality of life, including prolonging survival. Recently, we have encountered a number of diagnostic algorithms that suggest algorithms for estimating the risk of tumor presence or the risk of progression of cancer, using statistical methods. Objectives: The aim of this work is to verify new biomarkers for the diagnosis of gastric cancer and to develop an optimal algorithm for their use. Further, to evaluate the importance of cytokeratin markers - Tissue Polypeptide Antigen (TPA) and Tissue Polypeptide Specific Antigen (TPS) for the diagnosis of metastatic colorectal carcinoma in the liver. To carry out a pilot study of FGF23 levels in people with colorectal carcinoma and other gastrointestinal tumors. Methods and patients: Patient samples were analyzed using immunoradiometric, chemiluminescence and fluorescence assays. For each solved problem,...
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Soluble cytokeratin fragments' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography